The importance of integrating Wetlia 8 mg into the public health system of Mexico lies in ensuring that more patients can benefit from this innovative therapy without cost being a barrier to timely treatment. Improving the control of visual diseases in the country is essential, and access to innovative treatments like Wetlia 8 mg plays a crucial role in this task.
It is fundamental that clinical practice in Mexico adopts these innovations to ensure better vision and quality of life for those suffering from visual diseases. Wetlia 8 mg, approved by the Federal Commission for the Protection against Sanitary Risks since 2023, is already available in the country, allowing patients to maintain their visual ability to perform daily activities.
In the words of Dr. Patricio Rodríguez Valdés, president of the Mexican Retina Association, "If these types of conditions are not treated in time, irreversible vision loss could occur, so timely diagnosis and early treatment can preserve vision as much as possible by stabilizing the disease and preventing its deterioration."
Wetlia 8 mg, an improved version of Aflibercept, significantly reduces the frequency of injection applications compared to the 2 mg version, facilitating adherence to treatment and improving the quality of life for patients. This reduction in the number of injections is especially relevant for patients with Age-Related Macular Degeneration (AMD) and Diabetic Retinopathy.
Dr. Karen Palacios, medical manager of the Ophthalmology area at Bayer Mexico, emphasizes that Wetlia 8 mg is an innovative medication that, in addition to being effective, reduces the stress and anxiety associated with frequent ophthalmological treatments. This therapeutic advance places the patient at the center of medical attention, prioritizing their quality of life.
With the increasing prevalence of visual diseases in Mexico and the growth of the population at risk of suffering from AMD and DME, it is crucial that doctors and patients are informed about treatment options that offer better disease control with less impact on quality of life. Wetlia 8 mg shows promise in this regard, allowing for extended injection intervals that facilitate the management of these diseases.
In summary, the prescription of Wetlia 8 mg benefits patients by reducing the number of injections required, thus improving their quality of life and allowing for a more efficient use of available medical resources. As these types of innovative therapies are incorporated into clinical practice, new opportunities arise to enhance the care of patients with visual diseases in Mexico.
